A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

Inclusion Criteria: * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * Evidence or history of clinically significant disease. * Past medical history of epididymitis, orchitis, sexually transmitted diseases (chlamydia, gonorrhea, etc.) or urinary tract infection. * History of prostatitis or prostate surgery. * Urinary catheterization or instrumentation within 12 months of screening. Inguinal or scrotal hernia. * Current or history of congenital genital abnormalities. * Baseline scrotal ultrasound scan showing unilateral or bilateral scrotal blood flow abnormalities or anatomic abnormalities (hydrocele, cysts, other), with the exception of small epididymal cysts and spermatoceles. * Any condition possibly affecting drug absorption (eg, gastrectomy). * Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing. * History of sensitivity to spironolactone, eplerenone, or related compounds. * Serum potassium \>5.5 mEq/L at screening or Day 0.